Tasigna 200 mg 28 hard gelatin caps

معلومات الدواء
الإسم التجاري Tasigna 200 mg 28 hard gelatin caps -
الإسم العلمي Nilotinib
السعر 5700.00 جنيها
الشركات المنتجة Novartis
الوصف والإستخدام
وصف الدواء بالعربية
وصف الدواء بالإنجليزية Indication for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).pharmacodynamics nilotinib is a transduction inhibitor that targets bcr-abl, c-kit and pdgf, for the potential treatment of various leukemias, including chronic myeloid leukemia (cml).mechanism of action chronic myelogenous leukaemia (cml) is caused by the bcr-abl oncogene. nilotinib inhibits the tyrosine kinase activity of the bcr-abl protein. nilotinib fits into the atp-binding site of the bcr-abl protein with higher affinity than imatinib, over-riding resistance caused by mutations. the ability of amn107 to inhibit tel-platelet-derived growth factor receptor-beta (tel-pdgfrbeta), which causes chronic myelomonocytic leukaemia, and fip1-like-1-pdgfralpha, which causes hypereosinophilic syndrome, suggests potential use of amn107 for myeloproliferative diseases characterised by these kinase fusions (stover et al, 2005- weisberg et al, 2005). amn107 also inhibits the c-kit receptor k

البدائل

لا يوجد لدينا بدائل مسجلة لهذا الدواء